Skip Navigation

Staff Detail

Skip sharing on social media links


Mofenson, Lynne Meryl

Formal Title:






Silver Spring ,MD 20905


Lynne M. Mofenson, M.D., is an infectious disease specialist and board-certified pediatrician who joined the MPIDB in 1989, when it was the Pediatric and Maternal AIDS Branch, and retired from the Branch in 2014. She received her M.D. from Albert Einstein College of Medicine with honors (Alpha Omega Alpha). Dr. Mofenson served as Branch Chief, responsible for overall program planning and the development and scientific direction of research studies and clinical trials in domestic and international pediatric, adolescent, and maternal HIV infection, disease, and AIDS, for many years until her retirement in 2014. She was also project officer for the NICHD-funded multi-site Domestic and International Pediatric/Perinatal HIV Clinical Studies Network, which conducts clinical trials in treatment and management of HIV infection in infants, children, adolescents, and women both domestically and internationally, often in collaboration with other Networks, such as the Pediatric AIDS Clinical Trials Group funded by the NIAID, the Adolescent Trials Network and the Pediatric European Network for Treatment of AIDS. She served as Executive Secretary for the U.S. Public Health Service guidelines for treatment of HIV-infected children, treatment of HIV-infected pregnant women and prevention of mother to child HIV transmission, and provided consultation to the World Health Organization on treatment guidelines in resource-limited countries.


Featured Items:

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at (PDF - 1.51. MB). 

Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at (PDF - 2.69 MB).

Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58 (No. RR-11) September 4, 2009


Publications (PubMed):

Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis.
Unresolved antiretroviral treatment management issues in HIV-infected children.
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Prevention of mother-to-child HIV-1 transmission--why we still need a preventive HIV immunization strategy.
Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.
Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection.
Protecting the next generation--eliminating perinatal HIV-1 infection.
Antiretroviral drugs to prevent breastfeeding HIV transmission.
Antiretroviral treatment for children with peripartum nevirapine exposure.
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
The challenges of success: adolescents with perinatal HIV infection.
Cognitive Function and Neurodevelopmental Outcomes in HIV-Infected Children Older than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study.
Tenofovir Treatment Duration Predicts Proteinuria in a Multi-Ethnic United States Cohort of Children and Adolescents with Perinatal HIV-1 Infection.
Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.
Combination antiretroviral use and preterm birth.
Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.
Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models.
Antiretrovirals in pregnancy: a note of caution.
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.
Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief.
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology